SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Follow-up) — Babe Didrikson Zaharias — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientMildred Ella Didrikson Zaharias
Date of birth1911-06-26
IdentifiersMRN HR-ML038-SYN-TD; SSN (made up) 000-38-4471
Document date1953-06-29
AuthorRosalind Vasquez-Thornbury, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Restaging after four doses of dostarlimab, and tiredness with cold hands. [S]

History of Present Illness

Ms. Didrikson Zaharias comes on the day of her fifth dose, after restaging MRI and sigmoidoscopy last week. The cold she had in early June cleared within a week and she had cycle 4 on time. Over the last month she has become tired again, with cold hands on the course, dry skin and slightly heavier legs; her weight is up 0.8 kg. At the sick visit four weeks ago the TSH was 5.8 mIU/L with a normal free T4. Her bowel movements are normal, with no bleeding, and she has had no diarrhea, rash, cough or breathlessness. Sex is comfortable again. She is playing 18 holes and has entered a club competition next month. [S]

ElementDetail
TreatmentDostarlimab cycles 1 to 4 on schedule; cycle 5 today
RestagingMRI: near-complete response; sigmoidoscopy: flat scar with a 5 mm shallow ulcer
New symptomsTiredness, cold hands, dry skin for a month
SportPlaying 18 holes; entered a club competition

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired for a month; weight 63.8 kg, up 0.8 kg
IntegumentaryPositiveDry skin; no rash
EndocrinePositiveCold hands; no thirst or headache
GastrointestinalNegativeNormal bowel movements; no bleeding or diarrhea; mild constipation
RespiratoryNegativeCough gone; no breathlessness
PsychiatricNegativePleased with the scans; PHQ-9 3; no thoughts of self-harm

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other morningOne tablet every other morningOral route1953-03-30activeS
Dostarlimab-gxly 50 mg/mL injection, 500 mg intravenously over 30 minutes every 3 weeks, for nine doses (six months)500 mg every 3 weeks for nine dosesIntravenous route1953-04-06 to 1953-09-21completedS
Levothyroxine 75 microgram oral tablet, one tablet by mouth each morning on an empty stomach, four hours apart from ironOne tablet each morningOral route1953-06-29activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1953-06-29Body height168cmS
1953-06-29Body weight63.8kgS
1953-06-29Body mass index (BMI) [Ratio]22.6kg/m2S
1953-06-29Systolic blood pressure114mm[Hg]S
1953-06-29Diastolic blood pressure72mm[Hg]S
1953-06-29Heart rate60/minS
1953-06-29Respiratory rate14/minS
1953-06-29Body temperature36.4CelS
1953-06-29Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1953-06-29Hemoglobin [Mass/volume] in Blood13g/dL12-15.5 g/dLNormalS
1953-06-29Leukocytes [#/volume] in Blood by Automated count610*3/uL4-11 10*3/uLNormalS
1953-06-29Platelets [#/volume] in Blood by Automated count26810*3/uL150-400 10*3/uLNormalS
1953-06-29Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
1953-06-29Potassium [Moles/volume] in Serum or Plasma4.2mmol/L3.5-5.1 mmol/LNormalS
1953-06-29Creatinine [Mass/volume] in Serum or Plasma0.75mg/dL0.59-1.04 mg/dLNormalS
1953-06-29Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1948)/1.73 sq M102mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1953-06-29Glucose [Mass/volume] in Serum or Plasma89mg/dL70-99 mg/dLNormalS
1953-06-29Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma20U/L7-35 U/LNormalS
1953-06-29Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L8-35 U/LNormalS
1953-06-29Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma70U/L35-104 U/LNormalS
1953-06-29Bilirubin.total [Mass/volume] in Serum or Plasma0.5mg/dL0.1-1.2 mg/dLNormalS
1953-06-29Albumin [Mass/volume] in Serum or Plasma4.4g/dL3.5-5 g/dLNormalS
1953-06-29Thyrotropin [Units/volume] in Serum or Plasma12.6m[IU]/L0.45-4.5 mIU/LHighS
1953-06-29Thyroxine (T4) free [Mass/volume] in Serum or Plasma0.6ng/dL0.8-1.8 ng/dLLowS
1953-06-29Carcinoembryonic Ag [Mass/volume] in Serum or Plasma2.1ng/mLUp to 3.0 ng/mL in non-smokersNormalS
1953-06-29Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S

Physical Exam

Vital signs recorded on 1953-06-29; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 63.8 kg; blood pressure 114/72, pulse 60; temperature 36.4 °C
NeckThyroid not enlarged or tender
SkinDry skin on the shins; no rash
NeurologicalAnkle reflexes with slightly slow relaxation
RectalWith her agreement and a chaperone: smooth, with a small firm irregularity at about 4 cm; no mass; no blood

Problems

ProblemClinical statusVerificationCodeProvenance
Bright red blood with bowel movements for about three months, with narrower stools, urgency, a feeling of incomplete emptying, and a firm, ulcerated mass felt on the back wall of the lower rectum at about 5 cm from the anal verge: a rectal cancer must be confirmed or excluded. Colonoscopy with biopsy booked this weekresolvedconfirmed K62.5S — Synthetic presenting problem anchored to the documented fatigue before her cancer diagnosis. Superseded by the diagnosis at the second visit.
Iron deficiency anemia from chronic rectal blood loss: hemoglobin 11.0 g/dL, MCV 77 fL, ferritin 9 ng/mL, with tirednessactiveconfirmed D50.0S — Synthetic finding anchored to the documented fatigue at the end of the 1952 season.
Adenocarcinoma of the low rectum, mismatch repair deficient (loss of MSH2 and MSH6; microsatellite instability high), cT3bN1M0 (stage IIIB) on pelvic MRI, lower edge 4 cm from the anal verge and about 1 cm above the anorectal junction, mesorectal fascia clear, no extramural venous invasion; CEA 5.8 ng/mL; synthetic modern detail linked to her documented cancer, whose site the sources do not record exactlyactiveconfirmed C20S — Synthetic histology, site, stage, mismatch repair status and course; the sources say she had cancer treated with a colostomy and call it colon cancer (R on the site). See sources.md.
Acute viral upper respiratory infection with cough and sore throat, a week before cycle 4 of dostarlimab; oxygen saturation and chest X-ray normal, so immune-related pneumonitis is unlikely; rapid influenza and COVID-19 tests negative; resolvedresolvedconfirmed J06.9S — Synthetic intercurrent illness; not a historical claim.
Immune-related primary hypothyroidism from dostarlimab, grade 2: tiredness and cold hands, TSH 12.6 mIU/L and free T4 0.6 ng/dL after four doses, following a mild TSH rise four weeks earlier; dostarlimab continuedactiveconfirmed E03.2S — Synthetic common immune-related adverse event of PD-1 blockade.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ImagingRestaging pelvic MRI and flexible sigmoidoscopyAbout every three months during treatmentUp to dateLast week: near-complete response on MRI; flat scar with a 5 mm shallow ulcer on sigmoidoscopy
ExaminationDigital rectal examinationAt each oncology visit during treatment; every three to four months in watch-and-waitCompleted todaySmooth, with a small firm irregularity at about 4 cm; no mass
LaboratoryCEAAt diagnosis, at each restaging, then every three to six months for two yearsCompleted today2.1 ng/mL, normal
LaboratoryBlood countBefore each dose of dostarlimab and at each visit; about four weeks after oral iron startsCompleted todayHemoglobin 13.0 g/dL, white cells 6.0, platelets 268
LaboratoryKidney and liver function and glucoseBefore each dose of PD-1 blockadeCompleted todaySodium 140, potassium 4.2 mmol/L; creatinine 0.75 mg/dL, eGFR 102; glucose 89 mg/dL; ALT 20, AST 22, alkaline phosphatase 70 U/L; bilirubin 0.5 mg/dL; albumin 4.4 g/dL
LaboratoryTSH and free T4At baseline, then every six weeks on PD-1 blockade; six weeks after any levothyroxine changeCompleted todayTSH 12.6 mIU/L, free T4 0.6 ng/dL: hypothyroidism; levothyroxine started; TSH checks four and five weeks apart since the last visit
ExaminationImmune-related adverse event review (diarrhea, rash, cough, breathlessness, fatigue, endocrine symptoms)Before each doseCompleted todayHypothyroidism, grade 2; no colitis, rash, pneumonitis or hepatitis
LaboratoryFerritin after oral ironAbout three months after startingDeferredMissed: the ferritin due about three months after oral iron began was not added to the restaging blood tests. No harm is expected, because the bleeding has stopped and the hemoglobin is normal; corrective action: ferritin added to the final restaging blood tests, and iron continued until then
SurveyDistress and depression screen (PHQ-9, GAD-7)At diagnosis, at each treatment phase, and at least yearlyCompleted todayPHQ-9 3; item 9 scored 0
Self-managementSexual health and body imageThrough treatmentCompleted todaySex comfortable again since the bleeding stopped
Self-managementPhysical activity and sportEach visitCompleted todayPlaying 18 holes; entered a club competition

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer (current version); summarized in Benson AB, et al. NCCN Guidelines Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw 2024;22(6):366-375 (PMID 39151454) (2026); Cercek A, et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med 2022;386(25):2363-2376 (PMID 35660797) (2022); Cercek A, et al. Nonoperative Management of Mismatch Repair-Deficient Tumors. N Engl J Med 2025;392(23):2297-2308 (PMID 40293177) (2025); Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021); CMID: Clinical Monitoring Intelligence Database, colorectal cancer, hypothyroidism and anemia monographs (2026)

Follow-up: Dostarlimab cycles 6 to 9 as booked; TSH and free T4 in six weeks; final restaging after cycle 9; preventive visit due. Next scheduled visit 1953-08-10: periodic adult preventive visit during immunotherapy. [S]